Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia

Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for 2 years after treatment. However, it is unknown if serial molecula...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Robert Puckrin, Eshetu G. Atenafu, Jaime O. Claudio, Steven Chan, Vikas Gupta, Dawn Maze, Caroline McNamara, Tracy Murphy, Andre C. Shuh, Karen Yee, Hassan Sibai, Mark D. Minden, Cuihong Wei, Tracy Stockley, Suzanne Kamel-Reid, Aaron D. Schimmer
Format:	Artigo
Sprog:	Inglês
Udgivet:	Ferrata Storti Foundation 2020-01-01
Serier:	Haematologica
Online adgang:	https://haematologica.org/article/view/9590
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!